BiomedDiscoveries

Biomed Valley Discoveries is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for unmet medical needs, particularly in oncology. Founded by Jim Stowers, the company operates as a unique entity funded by the Stowers Institute for Medical Research, allowing it to focus on high-impact translational science. Its lead program, ulixertinib (BVD-523), is a first-in-class ERK1/2 inhibitor currently being evaluated in Phase 2 clinical trials for patients with MAPK-mutated solid tumors. The company's pipeline also includes early-stage programs targeting the MAPK pathway and other critical oncogenic drivers. Biomed Valley Discoveries leverages deep biological insights to advance precision medicines through clinical proof-of-concept.